{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:11:20Z","timestamp":1773288680489,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterans Affairs Office of Academic Affiliations"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA037217"],"award-info":[{"award-number":["R01 DA037217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AA027634"],"award-info":[{"award-number":["R21 AA027634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UO1 DA041731"],"award-info":[{"award-number":["UO1 DA041731"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Psychiatric and substance use disorders represent barriers to smoking cessation. We sought to identify correlates of psychiatric comorbidity (CM; 2 diagnoses) and multimorbidity (MM; 3+ diagnoses) among smokers attempting to quit and to evaluate whether these conditions predicted neuropsychiatric adverse events (NPSAEs), treatment adherence, or cessation efficacy (CE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims and Methods<\/jats:title>\n                  <jats:p>Data were collected from November 2011 to January 2015 across sixteen countries and reflect the psychiatric cohort of the EAGLES trial. Participants were randomly assigned to receive varenicline, bupropion, nicotine replacement therapy, or placebo for 12 weeks and were followed for an additional 12 weeks posttreatment. NPSAE outcomes reflected 16 moderate-to-severe neuropsychiatric symptom categories, and CE outcomes included continuous abstinence at weeks 9\u201312 and 9\u201324.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 4103 participants included, 36.2% were diagnosed with multiple psychiatric conditions (20.9% CM, 15.3% MM). Psychiatric CM and MM were associated with several baseline factors, including male gender, nonwhite race or ethnicity, more previous quit attempts, and more severe mental health symptoms. The incidence of moderate-to-severe NPSAEs was significantly higher (p &amp;lt; .01) in participants with MM (11.9%) than those with CM (5.1%) or primary diagnosis only (4.6%). There were no significant (ps &amp;gt; .05) main effects or interactions with treatment condition for diagnostic grouping on treatment adherence or CE outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While having multiple psychiatric diagnoses increased risk of developing moderate-to-severe NPSAEs during a quit attempt, neither CM nor MM were associated with treatment adherence or odds of quitting. These findings reassure providers to advise smokers with multiple stable psychiatric conditions to consider using Food and Drug Administration (FDA)-approved medications when trying to quit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications<\/jats:title>\n                  <jats:p>Psychiatric MM may be associated with development of NPSAEs when smokers make a medication-assisted quit attempt, but it does not appear to be differentially associated with medication compliance or efficacy. Prescribing healthcare professionals are encouraged to not only promote use of FDA-approved pharmacotherapies by smokers with complex psychiatric presentations, but also to closely monitor such smokers for neuropsychiatric side effects that may be related to their mental health conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>NCT #<\/jats:title>\n                  <jats:p>NCT01456936.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ntr\/ntab056","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T03:13:44Z","timestamp":1617160424000},"page":"1646-1655","source":"Crossref","is-referenced-by-count":12,"title":["Psychiatric Comorbidity and Multimorbidity in the EAGLES Trial: Descriptive Correlates and Associations With Neuropsychiatric Adverse Events, Treatment Adherence, and Smoking Cessation"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-3056","authenticated-orcid":false,"given":"John B","family":"Correa","sequence":"first","affiliation":[{"name":"Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA"},{"name":"Department of Psychiatry, University of California\u2014San Diego, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin S","family":"McKenna","sequence":"additional","affiliation":[{"name":"Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA"},{"name":"Department of Psychiatry, University of California\u2014San Diego, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natassia","family":"Gaznick","sequence":"additional","affiliation":[{"name":"Semel Institute for Neuroscience and Human Behavior, University of California\u2014Los Angeles, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip A","family":"Saccone","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Dubrava","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Doran","sequence":"additional","affiliation":[{"name":"Mental Health Service, VA San Diego Healthcare System, San Diego, CA, USA"},{"name":"Department of Psychiatry, University of California\u2014San Diego, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M","family":"Anthenelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California\u2014San Diego, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2021082906105429000_CIT0001","volume-title":"WHO Global Report on Trends in Prevalence of Tobacco Smoking 2000\u20132025.","author":"World Health Organization","year":"2019","edition":"3"},{"key":"2021082906105429000_CIT0002","doi-asserted-by":"crossref","first-page":"(45)","DOI":"10.15585\/mmwr.mm6845a2","article-title":"Tobacco product use and cessation indicators among adults\u2014United States, 2018","volume":"68","author":"Creamer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"2021082906105429000_CIT0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/caac.21444","article-title":"Who\u2019s still smoking? Disparities in adult cigarette smoking prevalence in the United States","volume":"68","author":"Drope","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"2021082906105429000_CIT0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ypmed.2016.05.011","article-title":"A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders","volume":"92","author":"Weinberger","year":"2016","journal-title":"Prev Med."},{"issue":"7","key":"2021082906105429000_CIT0005","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2105\/AJPH.86.7.985","article-title":"Are smokers with alcohol disorders less likely to quit?","volume":"86","author":"Breslau","year":"1996","journal-title":"Am J Public Health."},{"issue":"2","key":"2021082906105429000_CIT0006","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2013.284985","article-title":"Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation","volume":"311","author":"Cook","year":"2014","journal-title":"JAMA."},{"key":"2021082906105429000_CIT0007","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health.","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"issue":"3","key":"2021082906105429000_CIT0008","doi-asserted-by":"crossref","first-page":"e0120581","DOI":"10.1371\/journal.pone.0120581","article-title":"Tobacco-related mortality among persons with mental health and substance abuse problems","volume":"10","author":"Bandiera","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"2021082906105429000_CIT0009","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.amepre.2016.06.007","article-title":"Smoking and the reduced life expectancy of individuals with serious mental illness","volume":"51","author":"Tam","year":"2016","journal-title":"Am J Prev Med."},{"key":"2021082906105429000_CIT0010","author":"World Health Organization","year":"2020"},{"key":"2021082906105429000_CIT0011","author":"Royal College of Physicians and Royal College of Psychiatrists","year":"2013"},{"key":"2021082906105429000_CIT0012","author":"Australian Government Department of Health","year":"2012"},{"issue":"6","key":"2021082906105429000_CIT0013","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/070674370905400604","article-title":"Treatment of tobacco dependence in mental health and addictive disorders","volume":"54","author":"Hitsman","year":"2009","journal-title":"Can J Psychiatry."},{"issue":"12","key":"2021082906105429000_CIT0014","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1360-0443.1996.tb03802.x","article-title":"The future of smoking cessation therapy in the United States","volume":"91","author":"Hughes","year":"1996","journal-title":"Addiction."},{"issue":"3","key":"2021082906105429000_CIT0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMp1105248","article-title":"Smoking and mental illness\u2014breaking the link","volume":"365","author":"Prochaska","year":"2011","journal-title":"N Engl J Med."},{"issue":"11","key":"2021082906105429000_CIT0016","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ntr\/nty123","article-title":"Considering systemic barriers to treating tobacco use in clinical settings in the United States","volume":"21","author":"Rojewski","year":"2019","journal-title":"Nicotine Tob Res."},{"issue":"10","key":"2021082906105429000_CIT0017","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.2105\/AJPH.2005.080382","article-title":"Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial","volume":"96","author":"Hall","year":"2006","journal-title":"Am J Public Health."},{"issue":"22","key":"2021082906105429000_CIT0018","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1001\/jama.2010.1769","article-title":"Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial","volume":"304","author":"McFall","year":"2010","journal-title":"JAMA."},{"issue":"14","key":"2021082906105429000_CIT0019","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/archinte.165.14.1600","article-title":"Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial","volume":"165","author":"Johnson","year":"2005","journal-title":"Arch Intern Med."},{"issue":"5","key":"2021082906105429000_CIT0020","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/add.13264","article-title":"Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial","volume":"111","author":"Sigmon","year":"2016","journal-title":"Addiction."},{"issue":"1","key":"2021082906105429000_CIT0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ntr\/ntw190","article-title":"Combination extended smoking cessation treatment plus home visits for smokers with schizophrenia: a randomized controlled trial","volume":"19","author":"Brody","year":"2017","journal-title":"Nicotine Tob Res."},{"issue":"9","key":"2021082906105429000_CIT0022","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/add.13415","article-title":"Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis","volume":"111","author":"Wu","year":"2016","journal-title":"Addiction."},{"issue":"1","key":"2021082906105429000_CIT0023","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12888-017-1419-7","article-title":"Smoking cessation in severe mental ill health: what works? An updated systematic review and meta-analysis","volume":"17","author":"Peckham","year":"2017","journal-title":"BMC Psychiatry."},{"issue":"2","key":"2021082906105429000_CIT0024","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13814789609162146","article-title":"Comorbidity or multimorbidity: what\u2019s in a name? A review of literature","volume":"2","author":"van den Akker","year":"1996","journal-title":"Eur J Gen Pract."},{"issue":"3","key":"2021082906105429000_CIT0025","first-page":"182","article-title":"Expanded conceptualization of multimorbidity to encompass substance use disorders and other psychiatric illness","volume":"28","author":"North","year":"2016","journal-title":"Ann Clin Psychiatry."},{"key":"2021082906105429000_CIT0026","doi-asserted-by":"crossref","first-page":"e5559","DOI":"10.1136\/bmj.e5559","article-title":"Managing patients with mental and physical multimorbidity","volume":"345","author":"Mercer","year":"2012","journal-title":"BMJ."},{"key":"2021082906105429000_CIT0027","author":"Academy of Medical Sciences","year":"2018"},{"issue":"12","key":"2021082906105429000_CIT0028","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.1016\/S2214-109X(18)30391-7","article-title":"Global Alliance for Chronic Disease researchers\u2019 statement on multimorbidity","volume":"6","author":"Hurst","year":"2018","journal-title":"Lancet Glob Health."},{"issue":"10037","key":"2021082906105429000_CIT0029","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet."},{"issue":"3","key":"2021082906105429000_CIT0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/da.22982","article-title":"Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial","volume":"37","author":"Ayers","year":"2020","journal-title":"Depress Anxiety."},{"issue":"2","key":"2021082906105429000_CIT0031","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/JCP.0000000000001015","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial","volume":"39","author":"Evins","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"2021082906105429000_CIT0032","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jad.2019.06.008","article-title":"Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: subgroup analysis of a randomized clinical trial","volume":"256","author":"Heffner","year":"2019","journal-title":"J Affect Disord."},{"key":"2021082906105429000_CIT0033","volume-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P).","author":"First","year":"2002"},{"key":"2021082906105429000_CIT0034","volume-title":"Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II)","author":"Gibbon","year":"1997"},{"issue":"7","key":"2021082906105429000_CIT0035","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)."},{"issue":"6","key":"2021082906105429000_CIT0036","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand."},{"issue":"3","key":"2021082906105429000_CIT0037","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1037\/0022-3514.63.3.452","article-title":"The aggression questionnaire","volume":"63","author":"Buss","year":"1992","journal-title":"J Pers Soc Psychol."},{"issue":"12","key":"2021082906105429000_CIT0038","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry."},{"issue":"1","key":"2021082906105429000_CIT0039","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ntr\/ntr137","article-title":"Determinants of tobacco use and renaming the FTND to the Fagerstr\u00f6m Test for Cigarette Dependence","volume":"14","author":"Fagerstr\u00f6m","year":"2011","journal-title":"Nicotine Tob Res."},{"issue":"6","key":"2021082906105429000_CIT0040","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-159-6-201309170-00005","article-title":"Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial","volume":"159","author":"Anthenelli","year":"2013","journal-title":"Ann Intern Med."},{"issue":"2","key":"2021082906105429000_CIT0041","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ntr\/nty033","article-title":"Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers","volume":"21","author":"Doran","year":"2019","journal-title":"Nicotine Tob Res."},{"issue":"8","key":"2021082906105429000_CIT0042","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/add.14208","article-title":"Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES","volume":"113","author":"West","year":"2018","journal-title":"Addiction."},{"issue":"6","key":"2021082906105429000_CIT0043","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s11606-019-04858-2","article-title":"Predictors of neuropsychiatric adverse events with smoking cessation medications in the randomized controlled EAGLES Trial","volume":"34","author":"Anthenelli","year":"2019","journal-title":"J Gen Intern Med."},{"key":"2021082906105429000_CIT0044","author":"Centers for Disease Control and Prevention","year":"2013"},{"issue":"6","key":"2021082906105429000_CIT0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/MLR.0b013e31820bf86e","article-title":"Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey","volume":"49","author":"Druss","year":"2011","journal-title":"Med Care."},{"key":"2021082906105429000_CIT0046","volume-title":"Smoking and Mental Illness Among Adults in the United States. The CBHSQ Report: March 30, 2017","author":"Lipari","year":"2017"}],"container-title":["Nicotine &amp; Tobacco Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ntr\/advance-article-pdf\/doi\/10.1093\/ntr\/ntab056\/39463148\/ntab056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ntr\/article-pdf\/23\/10\/1646\/40080130\/ntab056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ntr\/article-pdf\/23\/10\/1646\/40080130\/ntab056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T06:11:34Z","timestamp":1630217494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ntr\/article\/23\/10\/1646\/6206759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ntr\/ntab056","relation":{},"ISSN":["1469-994X"],"issn-type":[{"value":"1469-994X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,3,31]]}}}